CBG Stats & Data

• CBG appears non-intoxicating and clear-headed for most users, but human clinical evidence remains limited; treat it as an experimental supplement rather than a proven therapy.

• Quality control varies widely across hemp-derived products; insist on a recent third-party COA reporting potency (CBG/THC), residual solvents, pesticides, heavy metals, and microbial contaminants. Mislabeling and contamination have been repeatedly documented in cannabinoid products.

• To avoid unintended intoxication or drug testing issues, verify Δ9-THC is below legal thresholds in the final product (not just the source hemp) and be mindful that even trace THC can accumulate with frequent dosing.

• Like other lipophilic cannabinoids, oral exposure can be increased by high-fat meals. If you change meal fat content, re-titrate from a lower dose to avoid overshooting effects.

• Cannabinoids can cause transient postural hypotension and dry mouth/eyes; sit or lie down if lightheaded. Those on antihypertensives or α2-agonists (e.g., clonidine; brimonidine eye drops) should start at the low end and monitor blood pressure.

• Avoid driving or operating machinery until you know your response—drowsiness can occur at higher doses or with CNS depressants.

• Inhalation: avoid oils and thickeners (e.g., vitamin E acetate) and unknown diluents; use tested distillates only, at modest temperatures, to reduce thermal degradation products.

• Pregnancy/breastfeeding: cannabinoid exposure in pregnancy is associated with risks with THC-containing products; there are insufficient data for CBG. Best practice is to avoid unless medically justified.

• Pilot and preclinical data suggest potential anxiolytic and anti-inflammatory actions, but CBG is not a substitute for indicated treatments in serious conditions. Discuss with a clinician if using alongside prescription medicines.

• Human pharmacokinetics are not well established; expect interindividual variability and adjust intervals/doses conservatively.